Experimental drug tested for stubborn blood disorder – but trial cut short
NCT ID NCT05676697
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested the drug Linperlisib in just 4 adults with autoimmune hemolytic anemia (AIHA) whose disease did not improve after at least two prior treatments. The goal was to see if the drug could help control the disease by targeting a key immune pathway. However, the trial was terminated early, so we have very limited information on how well it worked or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Linperlisib (a PI3K delta inhibitor)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat autoimmune hemolytic anemia.
What could go wrong
This was a very small, early-phase trial (only 4 participants) that was terminated early, so results are limited and may not be reliable. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regenerative Medicine Center
Tianjin, Tianjin Municipality, China
-
Zhoukou Central Hospital
Zhoukou, Henan, China